sk&f-38393 has been researched along with Cancer of Pituitary in 2 studies
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leng, ZG | 1 |
| Lin, SJ | 1 |
| Wu, ZR | 1 |
| Guo, YH | 1 |
| Cai, L | 1 |
| Shang, HB | 1 |
| Tang, H | 1 |
| Xue, YJ | 1 |
| Lou, MQ | 1 |
| Zhao, W | 1 |
| Le, WD | 1 |
| Zhao, WG | 1 |
| Zhang, X | 1 |
| Wu, ZB | 1 |
| Senogles, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas[NCT03400865] | 30 participants (Anticipated) | Interventional | 2018-10-25 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for sk&f-38393 and Cancer of Pituitary
| Article | Year |
|---|---|
Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Autophagosomes; Autophagy; Cabe | 2017 |
The D2 dopamine receptor mediates inhibition of growth in GH4ZR7 cells: involvement of protein kinase-C epsilon.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Alprenolol; Animals; Apomorphine; Benzaz | 1994 |